Name | Type | Posted | Actions |
|---|---|---|---|
RFI-26-08-PBD1_FINAL.docx | DOCX | Jun 3, 2026 |
RFI - Protection Before Day One Vaccine: Seasonal Influenza Vaccines with Pandemic Coverage
Contact and place of performance
Wendy Rehman
Washington, DC 20024
USA
“ Protection Before Day One Vaccine: Seasonal Influenza Vaccines with Pandemic Coverage ” Request for Information (RFI) 1.0 Background Influenza viruses remain a persistent and evolving threat to public health in the United States and globally. Seasonal influenza epidemics cause significant morbidity and mortality each year, while novel zoonotic influe...
View moreModeling suggests that Day One vaccines can not only reduce the total number of infections and peak infection rate but also delay the peak to allow more time for strain-matched pandemic vaccines to become available. In addition to the population-level benefits, Day One vaccines would also benefit individual vaccine recipients by reducing the risk of severe disease. Even with modest effectiveness, receiving a Day One vaccine could reduce an individual’s hospitalization risk by 35%.
Through this RFI, BARDA seeks to understand the availability of candidate Day One vaccines, including their development maturity, technical feasibility, manufacturing readiness, and regulatory considerations associated with vaccine candidates intended to meet this dual-benefit profile.
Please see full Request for Information attached.
The Administration for Strategic Preparedness and Response (ASPR) and the Biomedical Advanced Research and Development Authority (BARDA) issued this Request for Information (RFI) to evaluate the availability, technical feasibility, and development maturity of "Protection Before Day One" influenza vaccines. These candidate vaccines are intended to provide seasonal influenza protection while simultaneously offering partial protection against emerging pandemic influenza viruses at the onset of a public health emergency. This initiative seeks to address a critical vulnerability in current pandemic preparedness, specifically the three-month gap between the identification of a novel strain and the large-scale deployment of strain-matched vaccines.
This market research is identified under solicitation number RFI-26-08-PBD1 and categorized under NAICS 541714 for Research and Development in Biotechnology (except Nanobiotechnology) and PSC AN42 for Health R&D Services; Health Care - Other; Applied Research. BARDA aims to identify vaccine candidates that can reduce population-level infection rates and individual hospitalization risks before strain-matched vaccines become available. The inquiry includes a focus on manufacturing readiness and the regulatory considerations associated with vaccines meeting this dual-benefit profile.
The notice is a Sources Sought with no set-aside designated. Responses are due by July 15, 2026, and the primary place of performance is Washington, DC. Additional details are contained in one attachment titled RFI-26-08-PBD1_FINAL.docx, which was published alongside the notice on June 3, 2026. Wendy Rehman serves as the point of contact for this RFI.
Generated by Lumen AI
Scoped analysis and attachments—go beyond the summary when you need detail from the solicitation package.